$2.7bil in total revenue at $750 per unit (Qbrexzas price).
or $1.94bil profit at $540 per unit.
Being 3% of the 10m suffers aka 8% of the patients that are currently seeking treatment (3.7m) from a dermatologist. both seem very achievable.
they say when you start a new biotech product you should be assuming at least 10% market share.
Being a first line treatment you'd expect dermatologists to be easily be recommending this to more than 1 in 10 patients that come to see them bout this issue.
$2.7bil in total revenue at $750 per unit (Qbrexzas price). or...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.010(3.33%) |
Mkt cap ! $456.7M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 28.3¢ | $1.540M | 5.299M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 405243 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 110728 | 2 |
View Market Depth
| Last trade - 16.10pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
28.8¢ |
Change
-0.010 ( 3.81 %) |
||||
| Open | High | Low | Volume | ||
| 30.0¢ | 30.0¢ | 28.3¢ | 2718432 | ||
| Last updated 15.59pm 27/05/2024 ? | |||||
| BOT (ASX) Chart |